What are statins?
Statins are a class of medication that lower the level of LDL ("bad") cholesterol in the blood by reducing the amount the liver produces. They are the most widely prescribed cholesterol-lowering treatment in the world, and one of the most thoroughly studied drugs in the history of medicine.
They work by blocking an enzyme in the liver called HMG-CoA reductase — the key step in the body's cholesterol-making process. With this enzyme partially blocked, the liver produces less cholesterol and draws more LDL from the bloodstream, lowering circulating levels.
The most commonly prescribed statin in the UK is atorvastatin (Lipitor), usually at a dose of 20mg for prevention in people at higher risk, or 80mg for those who already have established cardiovascular disease. Other statins include rosuvastatin (Crestor), simvastatin (Zocor), and pravastatin (Pravachol) — each with slightly different profiles and strengths.
Statins are taken once daily, usually in the evening, and are intended as long-term treatment. In clinical practice, statin therapy is initiated alongside lifestyle measures — the two are complementary, not alternatives to each other.
Key Terms
Why does it matter?
Statins are one of the most important tools available for preventing heart attacks and strokes — both in people who have already had a cardiovascular event, and in those at higher risk of a first one. The evidence base is vast, the benefits are well-established, and yet they remain significantly underused — largely because of widespread concern about side effects that the best available evidence does not support.
Getting statin therapy to more of the people who need it is one of the NHS's top cardiovascular priorities. Better treatment rates could prevent tens of thousands of heart attacks and strokes each year.4
How many people does statin therapy actually help?
An effective course of statin therapy — such as atorvastatin (Lipitor) 40mg daily taken by 10,000 patients for five years — would typically prevent major cardiovascular events in around 1,000 people with pre-existing cardiovascular disease, and in around 500 people who have not yet had an event but are at increased risk. Each dot below represents one person.
What your doctor might do
Who is offered a statin?
Under current NICE guidance (NG238), statins are offered to anyone with established cardiovascular disease regardless of their cholesterol level, anyone without existing cardiovascular disease but with a 10-year QRISK3 score of 10% or above, and people aged 85 and over where age alone is considered sufficient to warrant consideration.
For people with a QRISK3 score below 10%, statins can now be considered — particularly if lifestyle changes alone have not been sufficient, and if the person prefers to take a statin after being informed of the risks and benefits.
Which statin and at what dose?
In the UK, atorvastatin (Lipitor) is the recommended first-choice statin because of its strong evidence base and very low cost as a generic medicine:
| Situation | Recommended statin and dose |
|---|---|
| Primary prevention (no existing CVD) | Atorvastatin (Lipitor) 20mg daily |
| Secondary prevention (existing CVD) | Atorvastatin (Lipitor) 80mg daily |
| Chronic kidney disease | Atorvastatin (Lipitor) 20mg daily |
Before starting and monitoring
Before prescribing a statin, a GP carries out baseline blood tests — a full lipid profile, liver function tests, and blood glucose. Existing muscle symptoms are noted and any medications that might interact with statins are reviewed.
Cholesterol levels are checked again at three months. The target for primary prevention is a reduction of more than 40% in non-HDL cholesterol. For secondary prevention the target is an LDL of 2.0 mmol/L or below, or a non-HDL of 2.6 mmol/L or below.
If statins are not tolerated
Where side effects occur, options include a lower dose, a different statin, or an alternative-day dosing schedule. Where statins genuinely cannot be tolerated, ezetimibe (Ezetrol) is the main alternative recommended by NICE.
What the research shows
The Cholesterol Treatment Trialists' Collaboration — the world's largest pooled analysis of statin trial data, drawing on data from over 170,000 participants across 26 randomised trials1 — has consistently found that each 1 mmol/L reduction in LDL cholesterol reduces the risk of major cardiovascular events by approximately one fifth. This benefit holds across men and women, across all age groups studied, and regardless of starting cholesterol level.
There is more misinformation about statin side effects online than about almost any other widely used medicine. The evidence from large randomised trials — where neither patients nor doctors know who is taking a statin and who is taking a placebo — tells a very different story.
A landmark meta-analysis by the CTT Collaboration, published in The Lancet (2022)2, drew on individual participant data from 23 large randomised trials involving over 150,000 people. It found that statins caused only a small excess of mostly mild muscle pain. The small increase in muscle symptoms was largely confined to the first year of treatment. After year one, low and moderate intensity statins caused no significant increase in muscle symptoms compared with placebo.
The ASCOT-LLA trial3 found that when patients knew they were taking a statin, muscle-related symptoms were 41% more likely compared with those who did not know. When the same patients were blinded — unaware whether they were taking a statin or placebo — the rate of muscle symptoms was virtually identical in both groups. This is the nocebo effect (the expectation of harm leading to real, experienced symptoms) in action.
The genuine risks — what does exist
The following risks are real, established, and worth knowing about — but must be understood in their proper context:
| Risk | How common | Notes |
|---|---|---|
| Mild muscle pain | Only ~1 in 15 muscle symptom reports are actually caused by the statin | Most muscle pain in statin users would have occurred anyway |
| Myopathy | Very rare — ~1 per 10,000 person-years | Risk increases with higher doses and certain drug interactions |
| Rhabdomyolysis | Extremely rare — ~2–3 per 100,000 person-years | Severe muscle pain accompanied by dark urine is a clinically recognised pattern warranting prompt medical assessment |
| New-onset diabetes | Small — ~0.2% per year of treatment | Mainly in those already at higher risk; cardiovascular benefits outweigh this risk |
| Liver enzyme rise | Up to 1% of patients | Usually mild and not clinically significant; severe liver damage is extremely rare |
A 2026 Lancet analysis of adverse effects listed on statin product labels5 — reviewing evidence from large double-blind randomised trials — concluded that most commonly cited side effects listed on statin packaging are not supported by causal evidence from randomised trials. The analysis called on regulatory authorities worldwide to revise statin labels to reflect the actual evidence.
Putting it all together
Statins are among the most effective and best-evidenced medicines in cardiovascular prevention. For people at significant cardiovascular risk, the benefits — measured in heart attacks and strokes prevented — substantially outweigh the genuine risks. Concern about side effects is understandable, but the blinded trial evidence is clear: most reported muscle symptoms are not caused by the drug.
Whether a statin is right for any individual — weighing risk profile, other medications, and personal preference — is a conversation for you to have with your GP or healthcare professional.
References
This article is for health education only. It is not a substitute for medical advice, diagnosis, or treatment. Anything personally relevant is a conversation for you to have with your GP or healthcare professional.